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Abstract
Background: Cathelicidins and defensins are endogenous antimicrobial peptides (AMPs) that are downregulated in the
mucosal epithelia of the large intestine in shigellosis. Oral treatment of Shigella infected rabbits with sodium butyrate (NaB)
reduces clinical severity and counteracts the downregulation of cathelicidin (CAP-18) in the large intestinal epithelia.
Aims: To develop novel regimen for treating infectious diseases by inducing innate immunity, we selected sodium 4-
phenylbutyrate (PB), a registered drug for a metabolic disorder as a potential therapeutic candidate in a rabbit model of
shigellosis. Since acute respiratory infections often cause secondary complications during shigellosis, the systemic effect of
PB and NaB on CAP-18 expression in respiratory epithelia was also evaluated.
Methods: The readouts were clinical outcomes, CAP-18 expression in mucosa of colon, rectum, lung and trachea
(immunohistochemistry and real-time PCR) and release of the CAP-18 peptide/protein in stool (Western blot).
Principal findings: Significant downregulation of CAP-18 expression in the epithelia of rectum and colon, the site of Shigella
infection was confirmed. Interestingly, reduced expression of CAP-18 was also noticed in the epithelia of lung and trachea,
indicating a systemic effect of the infection. This suggests a causative link to acute respiratory infections during shigellosis.
Oral treatment with PB resulted in reduced clinical illness and upregulation of CAP-18 in the epithelium of rectum. Both PB
and NaB counteracted the downregulation of CAP-18 in lung epithelium. The drug effect is suggested to be systemic as
intravenous administration of NaB could also upregulate CAP-18 in the epithelia of lung, rectum and colon.
Conclusion: Our results suggest that PB has treatment potential in human shigellosis. Enhancement of CAP-18 in the
mucosal epithelia of the respiratory tract by PB or NaB is a novel discovery. This could mediate protection from secondary
respiratory infections that frequently are the lethal causes in dysentery.
Citation: Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, et al. (2011) Phenylbutyrate Counteracts Shigella Mediated Downregulation of Cathelicidin in Rabbit
Lung and Intestinal Epithelia: A Potential Therapeutic Strategy. PLoS ONE 6(6): e20637. doi:10.1371/journal.pone.0020637
Editor: Hong Wei Chu, National Jewish Health, United States of America
Received December 21, 2010; Accepted May 6, 2011; Published June 3, 2011
Copyright:  2011 Sarker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Swedish Agency for Research Cooperation with Developing Countries (Sida/SAREC Agreement support; grant 2005–
2007), The Swedish Research Council, Cancerfonden, The Swedish Strategic Foundation (SSF), Thorsten and Ragnar So ¨derberg’s Foundations, The Swedish
Institute, Karolinska Institutet, International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B), The Icelandic Centre for Research (RANNIS) and
University of Iceland research fund. ICDDR,B acknowledges with gratitude the commitment of Sida/SAREC to the Centre’s research efforts. ICDDR,B also gratefully
acknowledges the following donors which provide unrestricted support to the Centre’s research efforts: Australian Agency for International Development
(AusAID), Government of the People’s Republic of Bangladesh, Canadian International Development Agency (CIDA), Embassy of the Kingdom of the Netherlands
(EKN), Swedish International Development Cooperation Agency (Sida), Swiss Agency for Development and Cooperation (SDC), and Department for International
Development, United Kingdom (DFID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Birgitta Agerberth, Gudmundur H. Gudmundsson, Roger Stromberg and Rubhana Raqib have a pending patent application for the use of
phenylbutyrate to treat infections (Publication No.: WO/2009/087474, International Application No.: PCT/IB2008/003709, Publication Date: 16.07.2009,
International Filing Date: 11.12.2008, Chapter 2 Demand Filed: 09.11.2009). Details of the patent can be found at http://www.wipo.int/pctdb/en/wo.
jsp?WO=2009087474&IA=IB2008003709&DISPLAY=ST. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: rubhana@icddrb.org
. These authors contributed equally to this work.
Introduction
Antimicrobial peptides (AMPs) are gene encoded antibiotics and
important components of the innate defense system, which protect
host-microbe interfaces from pathogenic insults [1]. We have
earlier shown that the human cathelicidin LL-37 and b-defensin-1
are downregulated in rectal epithelium of patients with shigellosis,
suggesting a mechanism facilitating bacterial invasion [2]. This
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20637finding was recently confirmed by Sperandio B et al. [3].
Additional pathogens such as Vibrio cholerae, enterotoxigenic
Escherichia coli and Neisseria gonorrhoeae also downregulate LL-37
expression in epithelial cells at the respective infection site,
indicating a common immune escape strategy by pathogens
[2,4,5]. Furthermore, LL-37 regulates tissue homeostasis and
sustains the integrity of the mucosal barrier as shown in respiratory
and intestinal tracts [6,7].
AMPs are attractive candidates for developing alternative
strategies in combating pathogens that become resistant to classical
antibiotics. These defense peptides exhibit broad spectrum of
antimicrobial activities and low incidence of bacterial resistance
[8]. We and others have shown that short chain fatty acids, in
particular butyrate, up-regulate LL-37 expression in colonic
epithelial cells [9,10]. In fact, butyrate is a fermentation product
of fibers in the colon and hence is present in the lower part of the
gut. We further demonstrated that oral treatment with sodium
butyrate (NaB) could restore the downregulation of rabbit
cathelicidin CAP-18 in the colonic epithelium of Shigella infected
rabbits with concomitant reduction in clinical severity and
bacterial load in stool [11]. However, butyrate is a foul-smelling
substance and is thus not suited for oral therapeutic interventions.
Recently we discovered that sodium 4-phenyl-butyrate (PB), an
odorless derivative of butyrate, is an even more potent inducer of
cathelicidin in vitro than butyrate [12]. Here we have investigated
the in vivo efficiency of PB compared to that of NaB treatment by
utilizing a rabbit model of shigellosis. Since shigellosis is often
associated with secondary respiratory infections [13,14,15], we
further investigated cathelicidin expression in lung and trachea
during Shigella infection as well as the remote systemic effect of oral
treatment with PB and NaB.
Results
Clinical responses of dysenteric rabbits are improved by
oral treatment with PB or NaB
Infected rabbits developed dysentery with thick liquid stool and
mucus, occasional blood in stool, reduced body weight, transient
fever, lethargy and anorexia, usually after 24 hours of infection.
Infected rabbits died within 48 hours if kept untreated. In contrast,
treated rabbits survived and recovered from the disease within 3–5
days of treatment as apparent by formed stool and revival from
lethargy and anorexia. The initial body weight loss, what was
prominent up to 2 days after infection was recovered by treatment
with PB or NaB (Fig. 1 A). The recovery of body weight by NaB
treatment was steady over time, while PB treatment led to a
significant recovery at day 3. Reduction of fever, pus cells,
macrophages and red blood cells were comparable in the 2
treatment groups (not shown). Thus, PB appears to ameliorate the
clinical symptoms of shigellosis in the rabbit model as demon-
strated earlier for NaB [11]. Since untreated infected rabbits could
not survive for longer period, the clinical features could not be
compared between treated and untreated rabbits.
Shigella load in stool is reduced by oral treatment with
PB or NaB
To investigate if the positive effects of PB or NaB treatment on
clinical symptoms were connected to reduction of the Shigella load
in gut, Kaplan-Meier survival plot analysis of colony forming unit
(CFU) in stool was performed. However, with PB treatment, most
rabbits (4 out of 5) stopped defecating after 2 days of treatment and
stool reappeared on 5
th day. Therefore, we also included CFU
count of rectal swab in this analysis. Treatment with PB or NaB
resulted in gradual reduction of Shigella shedding over time (Fig. 1
B) and no CFU was observed at day 4 and 5. The effect was
parallel in the two treatment group (p=0.62).
Release of CAP-18 peptide/protein in stool
By Western blot analysis of CAP-18 in stool extracts, only pro-
form of CAP-18 was observed in healthy and infected rabbits,
although band intensity varied between individual rabbits (Fig. 2).
As mentioned in the previous section, with PB treatment, stool
from only one rabbit could be obtained throughout the treatment
regime. In stool extracts from that single rabbit, the pro-form was
detected at higher levels from day 2 to 5. The processed form of
CAP-18 was also detected at low levels from day 2 to 5 (Fig. 2). In
the obtained stool samples at day 1, 2 and 5 from other PB treated
rabbits, higher levels of CAP-18 pro-form and low levels of active
peptide were also observed after treatment (not shown). The effect
of NaB has been demonstrated in our previous study [11] and was
reproduced here (not shown).
CAP-18 peptide/protein is downregulated in the mucosal
epithelia of large intestine and respiratory tract after
Shigella infection
Immunohistochemical analyses (Fig. 3 and 4) revealed signifi-
cant downregulation of CAP-18 peptide/protein after Shigella
infection in the epithelia of rectum (p=0.008) and distal colon
(p#0.001) compared to healthy rabbits. This is in line with our
previous result [11]. Interestingly, we also detected a significant
downregulation of epithelial CAP-18 in the lung (p=0.001) and
trachea (p=0.016) after Shigella infection compared to healthy
rabbits. No obvious changes in CAP-18 peptide/protein expres-
sion were observed in the non-epithelial region of the organs
investigated (Fig. 3).
CAP-18 peptide/protein is enhanced in the epithelia of
large intestine and respiratory tract in Shigella infected
rabbits after oral treatment with PB or NaB
In the rectal epithelium, treatment with PB significantly
(p=0.004) counteracted the Shigella mediated downregulation of
CAP-18 peptide/protein, while the effect of NaB was prominent
although not significant (p=0.07) compared to infected untreated
rabbits (Fig. 3 and 4). In the epithelium of distal colon, NaB
treatment significantly upregulated CAP-18 peptide/protein
expression as compared to infected untreated rabbits (p=0.003),
while PB exhibited no apparent effect.
Notably, oral PB (p=0.002) and NaB (p=0.024) treatment
significantly enhanced CAP-18 peptide/protein in the lung
epithelium compared to infected untreated rabbits (Fig. 3 and 4).
Moreover, treatment with NaB resulted in higher expression of
CAP-18 peptide/protein in the tracheal epithelium compared to
infected untreated rabbits, though the difference was not
significant. No change was evident in the tracheal epithelium
after PB treatment.
Thus, PB exhibits higher potency than NaB in inducing CAP-18
peptide/protein expression in the epithelia of rectum and lung,
while the effects on colonic and tracheal epithelia are not obvious.
NaB systemically induces CAP-18 peptide/protein
expression in the epithelia of large intestine and
respiratory tract
Butyrate is known to disseminate into blood after oral treatment
with NaB [16]. We also detected butyrate in rabbit serum in
particular at 30 minutes after oral treatment with a single
0.14 mmol dose of NaB (Fig. 5). Moreover, intravenous injection
of NaB into Shigella infected rabbits induced CAP-18 peptide/
Phenylbutyrate Affects Frontline Defenses
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20637Figure 1. Changes of infection associated events in Shigella infected rabbits before, during and after PB/NaB treatment. (A) Body
weight loss due to Shigella infection was recovered by treatment with PB or NaB. Data are given as mean 6 standard deviation of 5 rabbits in each
group. Two-way ANOVA with repeated measures on one factor (time) was used in comparing the effects over time between different groups. The
differences are significant when P,0.05; *significant loss of body weight compared to day 0 (healthy condition),
{significant recovery compared to
day 2. (B) Kaplan-Meier survival plot revealed reduction of Shigella CFU in stool of infected rabbits treated with PB (n=5) or NaB (n=5).Infected
untreated rabbits were sacrificed at day 2. PB: Sodium 4-phenylbutyrate, NaB: Sodium butyrate, CFU: Colony forming unit.
doi:10.1371/journal.pone.0020637.g001
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(Fig. 6).
The levels of CAP-18 transcripts during Shigella infection
and after oral treatment with PB or NaB
In an attempt to support our immunhistochemical data based
on ACIA-scores, mRNA levels in intestinal and respiratory tissue
extracts were measured. However, in contrast to the effect on the
peptide/protein level, Shigella infection resulted in increased CAP-
18 transcripts in lamina propria (LP) as well as in surface
epithelium (SE) of distal colon compared to healthy controls. The
increase was significant in LP (p=0.006) but not in SE (p=0.172).
Treatment with NaB significantly normalized the Shigella mediated
mRNA accumulation in both LP (p=0.006) and SE (p=0.008) in
the colon, whereas the effect of PB was significant only in LP
(p=0.016) compared to infected untreated rabbits. No obvious
changes in CAP-18 transcript levels were observed after infection
as well as after treatment with PB or NaB in both SE and LP of
rectum (Table 1).
During shigellosis, CAP-18 mRNA was increased significantly
in lung (p=0.006) and trachea (p=0.001) compared to healthy
controls. The levels of mRNA in both lung and trachea was
significantly normalized after treatment with PB (p=0.029 for
lung, p=0.004 for trachea) or NaB (p=0.029 for lung, p=0.001
for trachea) (Table 1).
Oral treatment with PB confers no toxic effect in rabbits
Since PB is a potential drug candidate for treatment of
infectious diseases, renal and hepatic biomarkers for toxicity were
monitored. No significant differences were observed in the plasma
levels of these biomarkers between healthy, healthy rabbits treated
with PB, infected and infected rabbits treated with PB (Table 2).
Similar results were observed earlier after NaB treatment of Shigella
infected rabbits [11].
Discussion
In the current study, we demonstrate for the first time that acute
Shigella infection despite being mostly a large intestinal infection
also downregulates the cathelicidin CAP-18 in the lung and
tracheal epithelial surfaces in a rabbit model. Treatment with
phenylbutyrate (PB) resulted in clinical recovery from shigellosis,
with clearance of Shigella from stool after 3–4 days of treatment.
Oral PB treatment counteracted the downregulation of CAP-18
peptide/protein in the rectal as well as in lung epithelia. PB is
approved as a drug for urea cycle disorder. Therefore, we propose
that PB can be evaluated in pharmaceutical intervention of human
shigellosis.
Our group first demonstrated that Shigella downregulates human
cathelicidin expression in epithelia of rectal biopsies and in colonic
epithelial and monocytic cell lines [2]. Interestingly, purified
plasmid DNA was indicated as the mediator of the downregula-
tion. Later, Sperandio et al. suggested plasmid-encoded effector
proteins, regulated by MxiE transcriptional activator being
responsible for Shigella mediated downregulation of innate effectors
including LL-37 [3]. However, the exact cell signaling pathways,
mediating downregulation of LL-37 have not yet been resolved,
although MxiE-driven effectors have been shown to target NF-kB
and MAPK signaling pathways [17,18,19].
We have previously shown that oral intake of sodium butyrate
(NaB) by Shigella infected rabbits led to reduced clinical severity,
reduced bacterial load in stool along with restitution of CAP-18
peptide/protein in the large intestinal epithelia and the conversion
of the pro-form of CAP-18 into its active form in stool [11]. Here,
we show that PB, a derivative of butyrate also mediated clinical
recovery from shigellosis. Oral PB treatment could also reduce
Shigella shedding in stool. By Western blot analysis, the active form
of CAP-18 was detected in stool after treatment with PB, which
supports the involvement of CAP-18 in in vivo bactericidal activity,
although additional antimicrobial components may also be
Figure 2. CAP-18 in stool of healthy rabbits, Shigella infected rabbits and infected rabbit treated with PB. Western blot analysis of CAP-
18 peptide/protein in stool extracts from 2 healthy, 2 Shigella infected and 1 infected rabbit treated with PB are shown. The 17 kDa pro-form of CAP-
18 was detected in the stool of healthy and infected rabbits before treatment. PB treatment resulted in increased levels of the pro-form and
appearance of low levels of the active CAP-18 peptide at day 2 (D2) and day 3 (D3); the level of active peptide was higher at day 4 (D4) that faded at
day 5 (D5). Synthetic CAP-18 peptide (1 ng) served as positive control. PB: Sodium 4-phenylbutyrate.
doi:10.1371/journal.pone.0020637.g002
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peptide/protein expression in both rectal and colonic epithelia,
PB upregulated CAP-18 only in rectal epithelium, indicating a
site-specific activity of PB. Given the increase of CAP-18 proform
in Western blot analysis of stool from PB treated rabbits, it is worth
noting that PB treatment not only recovers tissue levels of CAP-18
expression in the intestine but also significantly effects the secretion
of this antimicrobial peptide.
Earlier epidemiological studies have reported that dysentery and
cholera-like diarrhea outbreaks are often associated with second-
ary complications such as pneumonia and meningitis with a fatal
outcome [20,21]. In hospital based studies of patients with
dysentery or diarrhea, bronchopneumonia has often been the
underlying associated cause of death [13,14,15,22]. Here we
report a novel discovery that Shigella infection causes downregu-
lation of the antimicrobial peptide CAP-18 in lung and tracheal
epithelia. The Shigella associated downregulation of CAP-18
suggests a functional decline in the innate epithelial barrier of
the respiratory system, facilitating invasion by respiratory
pathogens. This may partially explain the frequent association of
pneumonia with shigellosis. The in vitro killing of respiratory
pathogens, Haemophilus influenzae and Moraxella catarrhalis by CAP-
18 (unpublished data) further supports this notion.
In the present study, we show that downregulation of CAP-18
peptide/protein was counteracted in lung epithelium, upon oral
intakeofPBorNaB.Thus,treatmentwith thesesubstancesseemsto
maintain expression of critically active components of the innate
defense barrier. Detection of butyrate in rabbit serum after oral
treatment with NaB suggest that orally administered NaB or PB are
absorbed from the intestine and reach the mucosa of various organs
viathebloodstreamand influenceCAP-18expression inthe remote
organs. Indeed, we found that intravenous injection of Shigella
infected rabbits with NaB also counteracted the downregulation of
CAP-18 peptide/protein in the epithelia of rectum, colon and lung.
Cellular pathways of cathelicidin induction by butyrate have
been studied in several human cell lines or primary cultures. The
Figure 3. CAP-18 expression in various mucosal tissues of healthy, infected, infected and PB/NaB treated rabbits.
Immunohistochemical technique was utilized to detect CAP-18 peptide/protein expression (brown staining) in the mucosal tissue sections of
rectum, distal colon, lung and trachea from healthy rabbits, Shigella-infected rabbits and infected rabbits treated orally with PB or NaB.
Representative pictures are shown. Original magnification was 6400 for all except for lung which was 6600. Row 1. The expression of CAP-18 in
enterocytes in the surface epithelium of rectum was reduced in infected rabbit compared to healthy rabbit. CAP-18 expression in the surface
epithelium of rectum in infected rabbit increased after treatment with PB or NaB. Row 2. CAP-18 expression in the distal colon was decreased in
enterocytes in the surface epithelium in infected rabbit compared to healthy rabbit. NaB amplified the CAP-18 expression in the surface epithelium of
colon in infected rabbit, while PB exhibited no apparent effect. Row 3. In lung, CAP-18 expression was located in the ciliated and mucus cells in the
epithelial layer and in the alveolar macrophages. Decreased expression of CAP-18 was observed in the lung epithelial layer of infected rabbit
compared to healthy rabbit. PB or NaB treatment led to increased expression of CAP-18 peptide in the lung epithelial lining of infected rabbit. Row 4.
CAP-18 expression was localized to the ciliated epithelium of the trachea. CAP-18 peptide was downregulated in the tracheal epithelium of infected
rabbit in comparison with healthy rabbit. Treatment with NaB counteracted this downregulation, while treatment with PB had no obvious effect. PB:
Sodium 4-phenylbutyrate, NaB: Sodium butyrate.
doi:10.1371/journal.pone.0020637.g003
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as histone deacetylase inhibitor (HDACi), facilitating transcription
[23,24]. The involvement of MAPK signaling pathways, nuclear
hormone receptors and transcription factor binding sites have also
been demonstrated [10,23,25,26]. Our group has recently shown
that, phenylbutyarte also involves activation of MAPK in lung
epithelial cells for CAMP gene (LL-37 encoding gene) induction
[12]. However, this study showed that the HDACi activity of PB is
not due to a direct effect on the chromatin structure at the CAMP
proximal promoter. Instead, enhanced histone acetylation facili-
tates expression of other genes, encoding critical factors, regulating
CAMP gene expression. An alternative pathway has also been
Figure 4. CAP-18 immunoreactivity in various mucosal epithelia of healthy, infected, infected and treated with PB/NaB rabbits.
Mucosal sections of rectum, distal colon, lung and trachea from healthy rabbits (n=5), Shigella-infected rabbits (n=5) and infected rabbits treated
orally with NaB (n=5) or PB (n=5) were stained with CAP-18 specific antibody. Quantification of immunoreactive area relative to the total cell area of
the epithelia was done by a computerized image-analysis technique, and the results are expressed as ACIA score, i.e., the total positively stained
area6total mean intensity (1–256 levels/per pixel) of positive area divided by total cell area (See materials and methods). Data are given as mean 6
standard deviation. One-way ANOVA (or ANOVA on ranks for data that were not normally distributed as assessed by Q-Q plot and histogram) was
used in comparing different groups of rabbits. The differences are significant when P,0.05;
{significant when compared to healthy, *significant when
compared to infected. PB: Sodium 4-phenylbutyrate, NaB: Sodium butyrate.
doi:10.1371/journal.pone.0020637.g004
Figure 5. Butyrate concentration in healthy rabbit serum over time after oral treatment with NaB. Serum was collected from healthy
rabbits at different time points after oral treatment with a single 0.14 mmol dose of NaB. Four analyses (duplicate analyses of two samples) of serum
from a NaB treated rabbit are shown, where the concentrations are calculated from two separate standard curves (one for each duplicate). NaB:
Sodium butyrate.
doi:10.1371/journal.pone.0020637.g005
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receptor (GPCR). Binding of short chain fatty acids including
butyrate to this receptor has been shown to affect inflammatory
and immune responses [27,28]. Butyrate-GPCR interaction might
also be involved in the induction of cathelicidin, an event that
needs to be addressed.
The levels of CAP-18 transcripts were enhanced in distal colon,
lung and trachea in Shigella infected rabbits compared to healthy
controls. These findings did not correlate with the CAP-18
peptide/protein expression in the mucosal epithelia of these
organs. We have earlier observed a similar finding in the rectum of
patients with shigellosis, where transcripts of several cytokines were
3–100 fold higher compared to the corresponding protein
expression [29]. These findings suggest a bacterial or host
mediated post-transcriptional regulation of certain cytokines and
in the present case also CAP-18. Shiga toxin or shiga-like
cytotoxins, which are known to inhibit host cell protein synthesis
[30,31] might be responsible for the observed low expression of
CAP-18 peptide/protein and accumulation of mRNA. Transla-
tional arrest at initiation and elongation has also been demon-
strated in influenza virus and adenovirus infections [32]. In our
earlier study of patients with shigellosis, the downregulation of LL-
37 transcripts in the gut mucosa was observed in the acute stage
and the proportion of patients with this downregulation increased
in the early convalescent stage [2]. In fact, the acute stage biopsies
were taken from patients between 3–5 days after onset of diarrhea
and thus it was not possible to evaluate whether there was an
initial upregulation followed by a decline in LL-37 transcripts in
the patients. In rabbits, the biopsies were collected within 24 hour
of infection; we could not keep the infected rabbits alive for longer
Figure 6. Comparison between intravenous and oral NaB treatment of Shigella infected rabbits on epithelial CAP-18
immunoreactivity. Immunostaining of CAP-18 peptide/protein was done in the tissue sections of rectum, distal colon and lung from healthy
rabbits (n=5), Shigella-infected rabbits (n=5), infected rabbits treated with NaB intravenously (IV) (n=2) or orally (n=5). A computerized image-
analysis technique was applied to quantify the immunoreactive area relative to the total cell area of the epithelia and the results are expressed as
ACIA score, i.e., the total positively stained area6total mean intensity (1–256 levels/per pixel) of positive area divided by total cell area (See materials
and methods). Data are given as mean 6 standard deviation. NaB: Sodium butyrate.
doi:10.1371/journal.pone.0020637.g006
Table 1. CAP-18 gene expression in the tissue specimens from various organs of healthy rabbits, Shigella-infected rabbits and
infected rabbits treated with PB or NaB.
Specimens Healthy rabbits Infected rabbits Infected rabbits treated with
(n=5) (n=5) PB (n=5) NaB (n=5)
Distal Colon, SE 11.6 (8.1–16.1) 22.2 (14.8–25.2) 14.3 (2–29) 5.02 (2.7–5.6)
b
Distal Colon, LP 0.42 (0.31–0.73) 19.7 (14.3–31.8)
a 0.53 (0.23–1.04)
b 0.55 (0.47–0.83)
b
Rectum, SE 0.77 (0.44–1.11) 0.93 (0.52–1.35) 0.18 (0.17–0.19) 0.3 (0.18–0.42)
Rectum, LP 0.18 (0.14–0.41) 0.12 (0.09–0.16) 0.41 (0.27–0.59) 0.1 (0.08–0.11)
Lungs 0.8 (0.65–2.11) 581.2 (530.9–735.5)
a 5.3 (2.7–8)
b 12.6 (10.4–15)
b
Trachea 1.14 (0.52–1.81) 36.3 (18.4–61.9)
a 1.1 (0.43–1.3)
b 0.71 (0.32–1.82)
b
Data are expressed as median with 25 and 75 percentiles in parentheses. Healthy control rabbits are without any treatment. One-way ANOVA on ranks was used in
comparing data between different groups of rabbits. The differences are significant when P,0.05;
asignificant when compared to healthy,
bsignificant when compared to infected. SE: Surface epithelium, LP: Lamina propria, PB: Sodium 4-phenylbutyrate, NaB: Sodium butyrate.
doi:10.1371/journal.pone.0020637.t001
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treatment. The production of high levels of CAP-18 mRNA
reflects a strategy of the host to intensify the innate defense to
protect against the invading pathogens. However, pathogens may
in someway interfere with the translation and thereby escape host
defense. Notably, after treatment with PB or NaB, the increase of
transcripts during infection was normalized, while the peptide/
protein expression was increased. The detailed mechanisms of this
post-transcriptional regulation need to be elucidated.
In summary, our results suggest phenylbutyrate to be a drug
candidate against shigellosis through its ability to counteract the
Shigella mediated downregulation of the gut’s innate epithelial
barrier. This oral treatment may also reinforce remote mucosal
immunity of the respiratory tract to combat secondary respiratory
infections, which are frequently associated with dysentery or
diarrhea. Further studies are underway to evaluate the potential
uses of phenylbutyrate in respiratory diseases.
Materials and Methods
Ethics statement
The study (Research protocol # 2007-065) was approved by the
Animal Experimentation Ethics Committee (AEEC) of the
International Centre for Diarrheal Disease Research, Bangladesh
(ICDDR,B) [May 07, 2008]. Based on the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health (NIH), ICDDR,B developed its own
rules and guidelines. These guidelines and the subsequent
modifications were approved by the ICDDR,B Board of Trustees.
Bacterial strain
An invasive clinical isolate of Shigella flexneri 2a as tested by the
Sere ´ny test and Congo red binding assay was used for infecting
rabbits [11].
Candidate compounds
Sodium butyrate (NaB) and sodium 4-phenylbutyrate (PB) were
obtained from Sigma-Aldrich, Steinheim, Germany.
Antimicrobial peptide CAP-18 and the corresponding
specific antibody
Synthetic CAP-18 peptide (GLRKRLRKFRNKIKEKLK-
KIGQKIQGLLPKLAPRTDY) (Innovagen, Lund, Sweden) is
the rabbit homologue of the human cathelicidin LL-37. Affinity
purified polyclonal chicken antiserum against CAP-18 (Innovagen)
recognizes both the proform and the mature CAP-18 peptide. The
proform/mature CAP-18 is designated as CAP-18 protein/
peptide in the manuscript.
Animal model
Inbred New Zealand white rabbits of either sex weighing 1.8–
1.9 kg were maintained in the animal resource facilities of
ICDDR, B. Healthy rabbits free of enteric pathogens e.g.,
Salmonella, Shigella, Vibrio cholera and Coccidia were studied. Rabbits
were infected with S. flexneri 2a to develop shigellosis. The infected
rabbits (n=15) were orally treated with PB (n=5) or NaB (n=5)
or left untreated (n=5). Expression of the CAP-18 protein/peptide
and mRNA in various specimens was analyzed in all the infected
and infected-treated rabbits and compared with healthy untreated
rabbits (n=5). Biosafety evaluation was done in infected rabbits,
infected rabbits treated with PB, healthy rabbits treated with PB
(n=5) and compared with healthy untreated rabbits (n=5).
Infection and treatment procedure
A nonsurgical rabbit model of shigellosis was used as described
[11]. Bacterial suspension [10
9 cfu in 7 ml of normal saline] was
given via a sterile feeding tube to each rabbit. After development
of dysenteric symptoms (usually within 24 h of inoculation), rabbits
of the treatment groups were given NaB (0.14 mmol/dose/rabbit)
or PB (0.14 mmol/dose/rabbit) in 7-ml of normal saline (pH 7.2)
orally twice daily for 5 consecutive days. Thereafter, rabbits were
sacrificed with an overdose of intravenous sodium pentobarbital
(66 mg/kg body weight; Sigma). Infected untreated rabbits were
sacrificed when the sufferings seemed intolerable, usually on the
2
nd day. Healthy rabbits were treated similarly with PB or left
untreated. The initial oral dose of butyrate (0.14 mmol/dose/
rabbit) was based on previous study [11]. The same dose was
selected for PB.
Specimen collection
Stool samples were collected before inoculating bacteria, after
development of dysenteric symptoms, and twice daily during
treatment. In parallel, rectal swabs were plated onto MacConkey
agar plates and incubated overnight at 37uC. After the rabbits
were sacrificed, blood was collected immediately by puncturing
the heart and serum and plasma were stored at 280uC. Tissue
biopsies of distal colon, rectum, lung and trachea were stored in
10% buffered formalin for immunohistochemical evaluation. For
quantitative real-time PCR, tissue specimens from lung and
trachea were collected directly in Trizol (Gibco-BRL, Auckland,
New Zealand). For colon and rectum, surface epithelia (SE) and
lamina propria (LP) were separated to discriminate between
epithelial cells and infiltrating immune cells. The separation was
performed using a previously described protocol [33] with slight
modifications. Briefly, tissue biopsies were washed extensively with
Ca
++/Mg
++ free PBS (CMF-PBS, pH 7.2) containing penicillin-
streptomycin. Tissues were then cut into small pieces followed by
incubation in extraction buffer containing 1 mM EDTA, penicil-
lin-streptomycin in CMF-PBS under stirring for 30 min at 37uC.
Detached epithelial cell suspension was spun down and stored in
Trizol at 280uC. Lamina propria cells were also stored in Trizol.
Clinical efficacy and biosafety of treatment
Clinical recovery of the rabbits from shigellosis was established
as described [11]. For biosafety evaluation, plasma collected after
the final treatment and from untreated rabbits were assessed for
Table 2. Levels of hepatic and renal markers in plasma of
healthy, Shigella infected and healthy/infected rabbits treated
with phenylbutyrate.
Rabbits Markers for kidney function Liver enzymes
Creatinine
(mmol/dL) Urea (mg/dL) ALT (U/L) c-GT (U/L)
Healthy 52.3627.6 32.5610.8 46.7615.9 7.564.0
Healthy+PB 67.8614.5 25.364.9 3564.9 7.662.7
Infected 209.16203.1 113.8670.8 75.3675.3 8.962.2
Infected+PB 68.465.0 31.6619.5 39.564.1 7.163.8
Data are given as mean 6 standard deviation. ALT Alanine transaminase; c-GT,
gamma glutamyl transferase. Plasma samples were collected after 3 days of
twice daily treatment with phenylbutyrate. Normal reference value of
creatinine, urea, ALT and c-GT for rabbits are 53–70.7 mmol/dL, 30–37.3 mg/dL,
,41 U/L and 0–14 U/L, respectively.
doi:10.1371/journal.pone.0020637.t002
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transferase) and renal markers (urea and creatinine) as performed
earlier upon butyrate treatment [11].
Bacterial count in stool
Bacterial load in stool was quantified by plating serial dilutions
of stool onto MacConkey agar plates and colonies were counted
after an overnight incubation at 37uC. The results were expressed
as colony forming units (CFU) per gram of stool. Rectal swab was
plated directly onto plate and colonies were counted after
overnight incubation.
Stool extraction and enrichment of peptide/protein
Stools were diluted 10 times with 60% acetonitrile in 1%
aqueous trifluoroacetic acid (TFA) and extracted overnight at 4uC.
The extracts were centrifuged and supernatants were passed
through a 0.45- mm filter and lyophilized. The lyophilized extracts
were dissolved in aqueous 0.1% TFA, enriched for peptides and
proteins by utilizing OASIS cartridges (Waters, Milford, Massa-
chusetts) as described [11] and again lyophilized. These peptide/
protein concentrates were used for Western blot analyses.
Western blot
Enriched peptide/protein extracts (approximately 30 mg) from
stool samples were separated with sodium dodecylsulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE), utilizing 4–12%
NuPAGE Ready Gels (Invitrogen, Carlsbad, CA, USA) followed
by electrophoretic transfer onto polyvinyldifluoride (PVDF)
membranes. Immunoreactivity was detected by subsequent
incubation of the membrane with affinity purified chicken
polyclonal CAP-18 antibody (0.2 mg/ml) and donkey-anti-chicken
IgY conjugated with horseradish peroxidase (Jackson Immunor-
esearch Laboratories Inc., West Grove, PA, USA). The enhanced
chemiluminescence (ECL) Western blot detection system (GE
Healthcare, Buckinghamshire, UK) was used to visualize the
bands.
Immunohistochemistry
Formalin fixed tissue pieces were embedded in paraffin and cut
into 3 micron thick sections. Sections were deparaffinized and
stained with the affinity purified chicken polyclonal CAP-18
antibody (6.8 mg/ml) (Innovagen) as described [11]. To control for
specific staining, synthetic CAP-18 was incubated at 20-fold-
higher concentration with the CAP-18 antibody overnight at 4uC,
and the mixture was used as above for immunostaining.
Image analyses
Immunohistochemical staining of CAP-18 in situ was analyzed
by using a microscope (Leica Microsystems GmbH, Wetzlar,
Germany) and the image analysis system Quantimate Q550
(Leica). The epithelial and non-epithelial areas were separately
assessed for quantification of CAP-18 staining in each tissue
section at 4006magnification and the results were given as ACIA
(Acquired Computerized Image Analysis) score [34] (see Support-
ing Information S1 for details).
Real-Time RT-PCR
RNA was extracted from biopsy specimens in Trizol, according
to the manufacturer’s instructions (Qiagen GmbH, Hilden,
Germany). Corresponding cDNA was synthesized using Super-
script III First-Strand Synthesis System (Invitrogen). CAP-18
transcripts, relative to the housekeeping 18S rRNA were measured
in triplicate from the cDNA samples by real-time quantitative RT-
PCR, using an Applied Biosystems PRISM model 7700 sequence
detection instrument (Applied Biosystems, Foster City, CA, USA)
and the 18S rRNA -housekeeping kit (Applied Biosystems). The
levels of 18S rRNA did not differ between controls, infected and
treated rabbits and was thus suitable as housekeeping gene. The
sequences of forward and reverse primers for CAP-18 transcript
were 59-GGAAGATGGGCTGGTGAAGC-39and 59-GCGCA-
GCCCAGTAGGTTCTG-39, respectively (Primer Express; Ap-
plied Biosystems). The TaqMan fluorogenic probe used for CAP-
18 was 6-FAM-CAACAGGGCCCAAGAG-MGB (Applied Bio-
systems). The results were analyzed by using the relative standard
method [5].
Butyrate in blood
To ensure that butyrate was disseminated via blood to act on
remote mucosal sites, Shigella infected rabbits (n=2) were injected
intravenously with 0.07 mmol/dose/rabbit of NaB (half of the
daily oral dose), twice daily for 3 days. Rectal, colonic and lung
tissues were collected and processed for CAP-18 immunostaining.
In addition, healthy rabbits (n=2) were orally treated with NaB
(0.14 mmol/dose/rabbit) and blood was collected from the ear
vein 15, 30, 45 and 60 minutes after treatment. Butyrate levels in
serum were determined by GC-MS based on the method by Su et
al. [35] with minor modifications (Supporting Information S2).
Statistical analyses
Statistical analyses were performed by using SigmaStat 3.1 for
Windows (Systat Software Inc., Point Richmond, CA, USA) and
SPSS 12.0 for Windows (SPSS Inc, Chicago, Illinois, USA). Data
were expressed as mean with standard deviation or median with
25–75 percentiles. Probabilities were regarded as significant when
P,0.05. Shigella CFU in stool was stated using Kaplan–Meier plot
and were compared between groups by using the log-rank
(Mantel–Cox) test. Clinical recovery over time between different
groups was analyzed by two-factor (treatment and time) ANOVA
with repeated measures on one factor (time). Differences in CAP-
18 immunostaining and CAP-18 transcripts among different
groups were analyzed by one-way ANOVA. For data that were
not normally distributed (as assessed by Q-Q plot and histogram),
ANOVA on ranks was applied.
Supporting Information
Supporting Information S1 Computerized image analy-
sis for detection of immunostaining.
(DOC)
Supporting Information S2 Analysis of butyrate in
serum.
(DOC)
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